ArticlePsychopharmacology2026
Targeting α5-GABAA receptors to restore dopamine system function in a translationally relevant model of perimenopausal psychosis.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPerimenopause marks a high-risk period for psychiatric instability, often precipitating or exacerbating disorders like schizophrenia. While traditional antipsychotics can be effective, they often worsen vasomotor symptoms and carry side effects that drive high discontinuation rates. We hypothesized that hippocampal hyperactivity, resulting from a decrease in GABAergic transmission, drives mesolimbic dopamine dysregulation in this state. Thus, we proposed that this circuit-level dysfunction can be reversed by targeting α5-containing GABA
methodsWe used the translationally relevant 4-vinylcyclohexene diepoxide (VCD) model of perimenopause, which mimics the progressive loss of ovarian follicles and hormonal instability seen in women. We assessed α5-GABA
resultsVCD-treated rats exhibited significantly elevated dopamine neuron population activity. This aberrant dopamine activity was completely reversed by systemic administration of MP-III-022.
conclusionsThese findings offer a pharmacologically distinct alternative to standard D2 receptor-targeted antipsychotics. Thus, modulating hippocampal-driven dopamine dysregulation via α5-GABA
Indexed as
Identifiers
42776198What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.